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Background/Aims
Recurrent nausea and/or vomiting are common complications of diabetes mellitus. The conditions severely impact the quality of life 
of patients and often cause repeated admissions to hospital incurring significant healthcare costs. If standard treatment fails, gastric 
electrical stimulation (GES) may be offered in selected cases, as a minimally invasive, but expensive, therapeutic option. Our aims are 
to evaluate the clinical effect and the cost-utility of GES as a treatment for severe diabetic recurrent nausea and/or vomiting.
Methods
Among 33 diabetes patients implanted with GES because of recurrent nausea and/or vomiting, 30 were available for evaluation. 
The effect of treatment was assessed prospectively using symptom-diaries and the SF-36 questionnaires at baseline, after 6 and 12 
months, and thereafter yearly. The number of days in hospital due to symptoms related to gastrointestinal dysfunction was calculated 
using hospital records 12 months prior to and 12 months after implantation.
Results
The surgical procedures were performed without mortality or major complications. Six months after surgery 78% of the respondents 
had at least 50% reduction in time with nausea and 48% had at least 50% reduction in days with vomiting. Symptom relief persisted 
at follow-up after at least 4 years. Quality adjusted life years improved after GES, which was cost-effective after 24 months. 
Conclusions
GES reduces symptoms and improves quality of life in diabetes patients with recurrent nausea and/or vomiting. The procedure is 
supposed as cost-effective over a 2-year time horizon.
(J Neurogastroenterol Motil 2017;23:541-549)
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Introduction  
Gastroparesis (GP) is defined as a chronic gastric emptying 
disorder with absence of mechanical obstruction.1 The 3 main 
groups of GP are diabetic, postsurgical, and idiopathic. The clinical 
characteristics of diabetes related GP include recurrent nausea and/
or vomiting, early satiety, bloating, and abdominal pain. Symptoms 
of GP typically occur at least 10 years after diagnosis of diabetes 
mellitus (DM).2 The estimated 10-year cumulative incidence of 
symptomatic GP is 5% in type 1 DM and 1% in type 2 DM.3 The 
condition is associated with significantly reduced quality of life and 
frequent admissions to hospital because of recurrent vomiting lead-
ing to dehydration and poor glycaemic control.4 The pathophysiol-
ogy of diabetic GP is not fully established, but it is associated with 
neuropathy of extrinsic and intrinsic neurons, abnormal function of 
smooth muscle cells, and neuropathy of glia cells and the interstitial 
cells of Cajal.5 The majority of diabetes patients with delayed gastric 
emptying remain asymptomatic, and severe symptoms can be pres-
ent even if gastric emptying tests are normal.6 Thus, treatment is 
usually initiated based on recurrent episodes of nausea and/or vom-
iting rather than a diagnosis of GP based on gastric emptying tests.
Dietary modifications are the first line of intervention for re-
current nausea and/or vomiting in diabetes patients. This is often 
insufficient and treatment is supplemented with prokinetics and 
antiemetics. If medical therapy fails, gastric electrical stimulation 
(GES) is a minimally invasive option. More extensive surgical pro-
cedures are only rarely performed as their rate of success is low and 
complications are common.7 Previous studies have shown that GES 
reduces nausea and/or vomiting and improves quality of life in pa-
tients with DM.8-11 GES is performed by a laparoscopic procedure 
and usually only requires a few days in the hospital. The stimulator is, 
however, relatively expensive and previous analysis of cost-utility was 
based on very few patients who mainly had idiopathic GP.12 Results 
from patients with idiopathic GP may not be directly applicable to 
patients with symptoms due to DM, as this group demonstrates 
progression in their condition, and often other diabetes related com-
plications might be present. Although definitive assessment of cost-
effectiveness may require long-term evidence from randomized 
trials, it is important early in the life-cycle of new technologies to 
begin to estimate likely cost-effectiveness.13 Such estimates can help 
prioritize new research and inform early adopters of the technolo-
gy.13,14 Thus, the aims of the present study were to assess the clinical 
effects of GES and to perform an early cost-utility analysis of GES 
for severe recurrent nausea and/or vomiting in patients with DM. 
Materials and Methods  
Patients
Between August 2005 and August 2013, 33 diabetes patients 
(16 men, median age 41 [range 23-75] years) with severe recurrent 
nausea and/or vomiting had a gastric electrical stimulator (Enterra 
Therapy; Medtronic Inc, Minneapolis, MN, USA) implanted at 
the Department of Abdominal Surgery, Aarhus University Hospi-
tal, Aarhus, Denmark. The department is currently the only one in 
Denmark performing this procedure. 
All patients had a history of recurrent episodes of severe nausea 
and/or vomiting for more than 12 months and none had sufficient 
relief of symptoms after dietary instructions and medical treatment 
for a minimum of 6 months. None of the patients had a history of 
major abdominal surgery and all had undergone standard evalua-
tion including upper endoscopy. 
Pre-operative Gastric Emptying Tests
Since the first GES was implanted at our department in 2005, 
the gastric emptying tests used had been refined from the radi-
opaque meal, to the paracetamol absorption test, and finally gastric 
emptying scintigraphy. Thus, gastric emptying was assessed using 
a radiopaque meal in 7 (4 prolonged), paracetamol absorption test 
in 18 (7 prolonged), or gastric emptying scintigraphy in 5 patients 
(1 prolonged). The paracetamol absorption test and gastric empty-
ing scintigraphy were performed according to previously published 
protocols.15,16 The radiopaque meal consisted of a veal steak, pota-
toes, sauce, and a glass of X-ray contrast. It was performed after at 
least 3 hours fasting with radiolucency performed for 2-3 minutes at 
baseline and again after 6 hours. 
Surgical Procedure
The GES was implanted under laparoscopic guidance under 
general anaesthesia. Access was through the umbilicus followed by 
a 5-mm port in the right flank and a 12-mm port in the lower left 
quadrant. Two intramuscular electrodes (Medtronic model 4351; 
Medtronic, Inc) were placed 1 cm apart along the major curvature 
approximately 10 cm from the pylorus. Upper endoscopy was per-
formed to ensure that the electrodes had not penetrated the gastric 
mucosa. The leads from the electrodes were extracted through 
the port in the lower left quadrant and connected to the pulse-
stimulator (Medtronic model 3116; Medtronic, Inc). The pulse-
stimulator was placed subcutaneously and sutured to the abdominal 
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fascia to the left of the umbilicus. A standard program was set for 
the stimulator (standard: Medtronic N’vision 8840; Medtronic, 
Inc; intensity 5 mA, frequency 14 Hz, pulse width 330 microsec-
onds, cycle on 0.1 seconds, cycle off 5 seconds). 
Pre-operatively 1500 mg of cephalosporin was given intrave-
nously and gentamicin sulphate was placed locally over the stimula-
tor. Post-operatively, the patients were restricted to a liquid diet for 
24 hours until discharged on their usual diet. If the patients did not 
have symptom relief the intensity of the current was increased from 
5 mA to 10 mA during follow-up at our outpatients’ hospital after 1, 
3, 6, and 12 months and hereafter yearly. 
Assessment of Symptoms and Quality of Life
The symptoms were evaluated by having patients fill in a di-
ary for 2 weeks before GES-surgery (baseline), 6 and 12 months 
post-surgery, and hereafter every year. The diaries were sent to the 
patients by mail or issued at scheduled visits in the outpatient’s 
hospital. The diaries included: episodes of vomiting (episodes/day), 
number of hours with nausea (hours/day), satiety (graded on a scale 
from 0 to 4, where 0 represents no satiety and 4 represents severe 
satiety), bloating (0 represents no bloating and 3 represents severe 
bloating), and general well-being (0 represents a state where the pa-
tient is able to do whatever she/he likes and 4 represents a miserable 
state where the patient is confined to bed). Vomiting was defined 
as a forceful expulsion of the contents of the stomach through the 
mouth. Reiterate expulsions at the same time only counted as one 
episode of vomiting. 
Alongside the diaries patients filled in the Short Form 36 health 
survey (SF-36). SF-36 is divided into 8 domains, which were added 
into the 2 summary scores: a physical component summary score 
and a mental component summary score. In each, 0 represents 
worst and 100 the best function (SF-36 version 1; RAND Cor-
poration, Santa Monica, CA, USA; http://www.rand.org/health/
surveys_tools/mos/mos_core_36item.html).
In the present paper, all data are given at baseline, 6, and 12 
months after surgery, and at long-term which is the longest follow-
up for each individual with a follow-up of at least 4 years. Our pre-
defined main criteria for success were: (1) at least 50 % reduction 
in time with nausea and (2) at least 50% reduction in the number of 
episodes with vomiting.
The study fulfilled the criteria within the Helsinki II declara-
tion and was approved by the Danish Data Protection Agency (Ref. 
No. 2007-58-0010).
Cost-utility Analysis
In order to generate quality adjusted life years (QALYs), SF-
36 data were converted to SF-6D using the algorithm by Brazier et 
al.17 Single imputation was used on missing data points. The total 
cost for the GES procedure was composed of the device cost, surgi-
cal procedure, 3 days of hospital admission in relation to surgery, 5 
out-patient visits before or after surgery, and costs for pre-operative 
endoscopy (Table 1). As 1 re-operation was performed in 1 of our 
30 patients, 1/30 of the surgical costs for that were added to all. 
One of the authors (L.S.M.) read hospital records of all the pa-
tients in this study and counted the number of days in hospital due 
to symptoms related to gastrointestinal dysfunction for 12 months 
prior to surgery and for 12 months after. Costs of hospital contacts 
were calculated from Danish diagnose related group (DRG) rates 
as given by the Danish healthcare authorities for the year of 2016.18 
According to these, the average cost of one day in hospital for a pa-
tient with the diagnosis DE108 (Type 1 diabetes with complication 
unspecified) or DE118 (Type 2 diabetes with complication unspeci-
fied) is 742 Euros (€). The DRG has a set trim point at 11 days, 
meaning that if patients are continuously in hospital for more than 
11 days, a lower extensive-stay rate of €265 is used. All costs were 
reported in Euros (1 € = 7.45 Danish kroner).
Table 1. Cost of Gastric Electrical Stimulation for Diabetes Patients With Recurrent Symptoms of Nausea and/or Vomiting.
Service Cost (€) No. Total cost (€)
Pre-operative outpatients hospital visit 76 1 76
Upper endoscopy 410 1 410
GES device 13.423 1 13.423
Laparoscopy 2.416 1 2.416
Post-operative follow-up visit in outpatients hospital 217 4 868
Re-operation for electrode adjustment 2.416 1/30 81
In hospital days related to surgery 742 3 2.226
Total cost per patient  19.500
GES, gastric electrical stimulation.
Costs are given in Euros (€).
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To test for uncertainties in the sample population, bootstrap re-
sampling was performed on both costs and effects at baseline, at 12 
months, and for an estimated 24-month’s sample. For each param-
eter the sample was re-sampled 500 times and confidence intervals 
for the mean were calculated. An incremental cost-effectiveness 
ratio (ICER) scatterplot was made to visualize the data in relation 
to an assumed Danish willingness to pay of €40.268 per QALY 
gained (corresponding to British pound (£) 30.000/QALY). Since 
there is no exact threshold value for the Danish decision-makers’ 
willingness to pay per QALY, we applied the £30.000/QALY pro-
posed by the British National Institute for Health and Care Excel-
lence to indicate a limit for what may be considered cost-effective.19
The “control group” used in the calculations were the patients’ 
own baseline data during the 12 months prior to surgery. 
Statistical Methods
All statistical calculations on patients’ symptoms were per-
formed using Stata Statistical Computer Program 2013 (STATA; 
StataCorp LP, College Station, TX, USA) with only descrip-
tive statistics performed. Quartile-quartile plots showed that data 
were not following normal distribution. Thus, results are given as 
median and full range and comparisons made with the Wilcoxon 
signed rank test and Mann-Whitney test. P-values < 0.05 were 
considered statistically significant. Calculations on cost-effectiveness 
were made in Microsoft Excel (Microsoft, Corp, Redmond, WA, 
USA). 
Results  
Study Population
Baseline data on symptoms were available for 30 of 33 patients 
(Fig. 1). These included 20 patients with type 1 DM and 10 with 
Patients returning their diary
at 6 months
n = 23
Patients returning their diary
at 12 months
n = 23
Patients returning their diary
after 4+ years
n = 13
Patients missing baseline data
n = 3
Diabetes patients with
implanted gastric electrical
stimulator as a treatment for
severe gastrointestinal
symptoms
N = 33
Figure 1. Flow diagram of the study 
cohort of diabetes patients with recurrent 
nausea and vomiting. Four patients died 
after 3, 3, 5, and 7 years of follow-up re-
spectively. Data were not complete. Thus, 
12 months follow-up included 4 patients 
who had not returned their diary at 3-6 
months whereas 4 years+ also included 
some patients who had not returned their 
diary at either 3-6 or 12 months.
Table 2. Summary Table Showing Descriptive Data in the Included 
Diabetes Patients in Numbers and Percent
 n (%)
Gender
    Women 15 (50)
    Men 15 (50)
Diabetes  
    Diabetes type 1 20 (67)
    Diabetes type 2 10 (33)
Death in follow-up period  
    Cause of death: purulent meningitis (1), 
      heart arrest (1), unknown (1), 
      disseminated lung cancer (1)
4 (13)
Diabetes complications before operation  
    Retinopathy 9 (30)
    Nephropathy 9 (30)
    HbA1C 74.5 mmol/mol
    Late onset diabetes complications 6 (20)
    Diabetic foot ulcer 6 (20)
    Kidney transplantation 0
    Dialysis 0
Weight before operation (median 25 [range 15.6-33.1])
    Underweight 2 (7)
    Normal 12 (41)
    Overweight 9 (31)
    Obese 6 (21)
Stomach emptying test  
    Gastric emptying scintigraphy 5 (17)
    Paracetamol absorption test 18 (60)
    Radiopaque meal test 13 (43)
Post-operative complications  
    Feeding tube (permanent) 1 (3)
    Death 0 (0)
    Re-operation to adjust the position of the Stimulator 1 (3)
    Pain in the subcutaneous pocket 3 (10)
    Diffuse abdominal pain 2 (7)
    Small seromas 2 (7)
    Small hematomas 1 (3)
HbA1C, glycated hemoglobin A1C.
545
Gastric Electrical Stimulation 
Vol. 23, No. 4   October, 2017 (541-549)
type 2 DM (Table 2). Median duration of diabetes was 21 (range 
3-37) years. Median time from debut of recurrent nausea and/or 
vomiting until GES implantation was 4 (range 1-10) years. 
Late complications to diabetes included retinopathy in 22 
(73%), nephropathy in 9 (30%), macrovascular disease in 6 (20%), 
and diabetic foot ulcer in 6 (20%) patients. None had received a 
kidney transplant or were in dialysis treatment before the GES 
operation. The median follow-up was 35 (range 1-120) months. 
During the follow-up period; 8 (27%) developed a diabetic foot ul-
cer, 5 (17%) started dialysis treatment, and 1 (3%) received kidney 
transplantation.
None of the batteries for the GES had exceeded its lifetime 
during the follow-up period.
Complications to Surgery
The surgical procedure was without mortality or major complica-
tions. The following minor complications were reported within 30 
days. Pain near the subcutaneous pocket for the stimulator (n = 3), 
diffuse abdominal pain (n = 2), small seroma (n = 2), and small 
hematoma (n = 1). None of the complications required surgical 
intervention. One patient required re-operation to adjust the position 
of the stimulator and another had a permanent jejunostomy feeding 
tube because of chronic malnutrition. Twenty-one of the patients had 
the current of the stimulator raised to 10 mA because of lack of effect. 
During the follow-up period four patients died of causes not related 
to the procedure (purulent meningitis [n = 1], unexpected cardiac 
arrest [n = 1], unknown [n = 1], disseminated lung cancer [n = 
1]). Death of the above occurred after 3, 3, 5, and 7 years respectively. 
Clinical Effects
At least 50% reduction in time with nausea was achieved 
in 78% of the diabetes patients after 6 months, in 30% after 12 
months, and in 75% at follow-up after at least 48 (median 96 [range 
48-120]) months. At least 50% reduction in episodes with vomiting 
was achieved in 48% of the diabetes patients after 6 months, in 43% 
after 12 months, and in 69% at follow-up after at least 48 (median 
96 [range 48-120]) months.
Changes in individual symptoms are shown in Table 3. At 6 
months follow-up there was a statistically significant improvement 
in vomiting, nausea, satiety, bloating, and general well-being. Most 
patients still reported improvement at long-term follow-up even 
though improvement of some symptoms did not reach statistical 
significance as the number of subjects became fewer (Table 3). The 
effect on symptoms did not differ between patients with normal or 
prolonged gastric emptying tests before implantation and GES. 
The median number of days in hospital was 4.5 (range 0-172) in 
Table 3. Symptoms of Included Patients With Diabetes at Baseline and After Gastric Electrical Stimulation
Symptoms
Baseline  
(median [range]) 
6 months 
(median [range])
12 months
(median [range]) 
At least 4 years 
(median [range])
Vomiting (episodes/wk) 4.5 [0-110]  1 [0-15] 
P = 0.009 
0.6 [0-21] 
P = 0.207 
0 [0-3.5] 
P = 0.004 
Nausea (hr/wk) 31.2 [0-112] 5 [0-31] 
P < 0.001 
11.5 [0-71] 
P = 0.003 
0.3 [0-26] 
P = 0.002
Satiety (scale 0-4) 2.2 [0-4] 1.4 [0-3.8] 
P = 0.003 
1.9 [0-4] 
P = 0.091
1.8 [0-4] 
P = 0.077
Bloating (scale 0-3) 2.1 [0-3] 1.8 [0-3] 
P = 0.032 
1.8 [0-3] 
P = 0.292
1.2 [0-3]
P = 0.077
Well-being (scale 0 [best]-4 [worst]) 2.4 [0.9-4] 1 [0-2.9]
P < 0.001
1.7 [0-7]
P = 0.032 
1.9 [0.1-3.3]
P = 0.583 
Baseline
1200
1000
800
600
400
200
4 years+
0
Physical
Mental
*
* *
6 months 12 months
SF-36 summary score
* *
Figure 2. Short form 36 health survey (SF-36) summary scores 
for physical and mental health at baseline and after gastric electrical 
stimulation. The highest possible scores in healthy individuals are 
respectively 2100 for physical and 1500 for mental health. Asterisk (*) 
shows significant changes compared to baseline.
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the 12 months before surgery, and 0 (range 0-74) during the 12 
months after (P = 0.005). 
The SF-36 summary scores for physical health and for mental 
health both improved significantly after 6 months, 12 months, and 
at long-term follow-up (Fig. 2). Before GES the median hemoglo-
bin A1C was 75 mmol/mol (9%) (range 45-128 mmol/mol), and 
following GES it was 76 mmol/mol (9,1%) (range 45-121 mmol/
mol) (P = 0.358). 
Cost-utility
Mean health economic costs were €16.611 per year at baseline 
and €26.549 at 12 months after GES implantation, giving an incre-
mental cost of €10.031. The incremental cost after 24 months was 
€104. The mean utility value was 0.5204 at baseline and 0.5963 at 
12 months follow-up, giving an incremental QALY of 0.0759 after 
one year with GES. The incremental QALY after 24 months was 
0.1539. This gives an estimated ICER after 24 months of €676 per 
QALY (Table 4). The computed bootstrap analysis of the ICER 
after 12 months follow-up and estimated 24-months follow-up (28 
patients) is shown in Figure 3.
Discussion  
The present study confirms previous studies demonstrating 
GES to be a safe and clinically effective procedure8,9,20,21 which im-
proves quality of life22 in a substantial proportion of highly selected 
patients with diabetes and severe recurrent nausea or vomiting. Our 
study is, however, the first to provide health economic-evaluation, 
and the data indicate that the procedure is cost-effective after 2 
years. As the lifetime of the GES-battery is at least 10 years and the 
clinical effects seem to persist during follow-up, the procedure must 
be considered to be very cost-effective over a longer range of years. 
GES has proven to be superior to placebo in 4 placebo-
controlled trials in patients with diabetic, post-surgical, or idiopathic 
recurrent nausea and/or vomiting.11,23-26 In a double-blinded, ran-
domized, crossover study, symptoms and quality of life improved 
significantly more while the stimulator was on than when off.11 
However, in another study from the same group, vomiting and 
nausea improved both during on and off periods.25 In a double-
blinded, randomized crossover study among 32 patients with 
idiopathic GP, nausea and vomiting improved non-significantly 
both with the stimulator on and off, but with a trend towards more 
improvement with the stimulator on. However, the lack of a wash-
out period between the on and off phases may have compromised 
the data in the study.23 Interpretation of the previously mentioned 
studies is hampered by a large variation in time between implanta-
tion of GES and inclusion into the randomized trials. Furthermore, 
the crossover design may not be appropriate for GES as the carry-
over effect and the necessary washout period are unknown. 
Table 4. Incremental Cost and Effects 12 Months and 24 Months After Surgery
Incremental cost (€) Incremental effect (QALY)
12 months 24 months 12 months 24 months
Mean 10 031 104 0.076 0.154
95% CI     9630-10431 –723-932 0.075-0.078 0.151-0.157
SD 4567 9454 0.019 0.038
Minimum-maximum –10 117-19 810 –35 059-19 599 0.018-0.131 0.057-0.279 
ICER (€/QALY) 132.161 676
€, Euro; QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.
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Figure 3. Bootstrap analysis showing incremental cost-effectiveness 
ratios at 12 months (blue) and estimated at 24 months (red) after gas-
tric electrical stimulation (GES). Data from the 28 patients included 
in the analysis were re-sampled 500 times for each patient. As seen in 
the figure, more samples are located under the line for willingness to 
pay (WTP) after 24 months (red) than after 12 months (blue). Based 
on the analysis GES was cost-effective after 24 months. QALY, qual-
ity adjusted life year.
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In spite of severe symptoms, only 12 of 30 of our patients had 
prolonged gastric emptying-time before GES. The poor correlation 
between symptoms and objective measures of gastric emptying is 
well known.6,27,28 Thus, the decision to offer the individual diabetes 
patient GES was based on a history of recurrent nausea and/or 
vomiting and not on a strict diagnosis of GP. 
GES is a relatively expensive procedure, mainly because of the 
price of the electrode and battery, which is approximately €13.000. 
The immediate cost is probably the major limitation to a more com-
mon use of the procedure. A previous study comparing the use of 
healthcare resources among patients with idiopathic GP having 
either GES or medical treatment concluded that GES was the most 
cost-effective. This study had 3 years follow-up, but it was unfor-
tunately not randomized.12 An open study among 37 patients, of 
whom 24 had diabetic GP, followed for 12 months found that days 
in hospital were significantly reduced after GES, but no cost-ef-
fectiveness analysis was performed.29 Our study is the first to focus 
on the early cost-effectiveness of GES in a population with diabetic 
recurrent nausea and/or vomiting. The data strongly indicate that 
GES is cost-effective after approximately 2 years and demonstrate 
that the clinical effect is maintained for a longer period of time. In 
a study on 188 patients, McCallum et al.9 found that the clinical 
improvement persisted up to 10 years. 
The mechanism of action of GES remains unclear. The current 
intensity is too low to cause contractions of the antrum or initiate a 
peristaltic wave.11 No associations between changes in symptoms 
and gastric emptying have been found.11 Changes in central control 
of nausea and vomiting mediated through the vagal nerve have 
been suggested. Thus, vagal activity increases during GES, which 
may increase the threshold for discomfort during gastric distension. 
Data indicate increased thalamic and caudate nuclei activity during 
chronic high-frequency GES therapy.30 In a canine model, gastric 
emptying during GES correlated well with plasma motilin levels. 
The authors concluded that motilin levels could be important to 
alter gastric motility during GES.31
The main limitations in the present study are the low number 
of patients and that the reduced cost from days in hospital between 
12 and 24 months was assumed to be the same as during the first 
year after GES. The “control group” used in the calculations was 
patients own baseline data during the 12 months prior to surgery. 
It is assumed that an actual control group would have the same 
amount of in-hospital days the following years as the patients had 
before surgery. A randomized placebo-controlled design has obvi-
ous advantages. However, such a design would have restricted 
the study period to weeks or a few months. All patients had severe 
symptoms and poor quality of life without sufficient relief from any 
other treatment attempted. The effect of GES on symptoms has 
been shown in previous studies, and for ethical reasons patients 
could only have been randomized to placebo/standard treatment 
for a relatively short period of time. Symptoms of gastroparesis are 
very variable and a much longer time is probably needed to estimate 
the cost/effect, especially in terms of number of days in hospital. 
Thus, we had to choose between a control group without GES that 
was followed for a relatively short period of time, or an appropriate 
follow-up period, which was compared to patients’ baseline data.
Compared to the 2 previous studies on cost-effectiveness of 
GES, our study included approximately the same number of pa-
tients. As the clinical effects were maintained after more than 2 
years, we find the assumption that the cost would be reduced too is 
valid. 
First line intervention against GP is dietary modification. 
Patients are asked to minimize the meal-content of fat and fibers 
and consume frequent but smaller meals. Liquid meals are recom-
mended because they require a minimum of mechanical process-
ing.7,32 In addition to that, hyperglycemia per se can cause delayed 
gastric emptying and it is important that patients control their blood 
glucose levels.33 
Medical treatment including antiemetics and prokinetics 
should be attempted. If medical therapy fails, GES or a jejunostomy 
feeding tube are alternatives to more extensive surgical procedures. 
Surgical interventions; as pyloric injection with botulin toxin,34 py-
loroplasty,35 and total or subtotal gastrectomy36 have been described 
but their effect is poorly documented.
In conclusion, our data support previous reports that GES is a 
safe procedure, which markedly reduces symptoms and improves 
quality of life in diabetes patients with recurrent nausea and/or vom-
iting. Our study is the first to perform an early regular cost-effective 
analysis of GES in diabetes patients with symptoms of GP. We 
found that GES reduced the days in hospital by 61% during the 
first year and that treatment seems to be cost-effective after a 2-year 
horizon. 
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